The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Open accessAbstract
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to approved TKIs. In this phase 3, open-label study, patients with CML-CP previously treated with ≥2 TKIs were randomized (2:1) to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily. Randomization was stratified by major cytogenetic response (MCyR) status at baseline. The primary objective was to compare the major molecular response (MMR) rate at week 24 for asciminib vs bosutinib. A total of 233 patients were randomized to asciminib (n = 157) or bosutinib (n = 76). Median follow-up was 14.9 months. The MMR rate at week 24 was 25.5% with asciminib and 13.2% with bosutinib. The difference in MMR rate between treatment arms, after adjusting for MCyR at baseline, was 12.2% (95% confidence interval, 2.19-22.30; 2-sided P = .029). Fewer grade ≥3 adverse events (50.6% vs 60.5%) and adverse events leading to treatment discontinuation (5.8% vs 21.1%) occurred with asciminib than with bosutinib. The study showed a superior efficacy of asciminib compared with that of bosutinib, together with a favorable safety profile. These results support the use of asciminib as a new therapy in patients with CML-CP who are resistant/intolerant to ≥2 prior TKIs. This trial was registered at www.clinicaltrials.gov as #NCT03106779.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationEuropean LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Self-citationThe allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Self-citationCortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2018) · Blood · doi:10.1182/blood-2016-09-739086 · Cited by 592
Self-citationCortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D.-W., Dyagil, I., Glushko, N., Milojkovic, D., le Coutre, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7162 · Cited by 495
Self-citationAsciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902328 · Cited by 471
Self-citationCortes, J. E., Kim, D.-W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7522 · Cited by 466
Self-citationDiscovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Schoepfer, J., Jahnke, W., Berellini, G., Buonamici, S., Cotesta, S., Cowan-Jacob, S. W., Dodd, S., Drueckes, P., Fabbro, D., Gabriel, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01040 · Cited by 454
for the SAKK and the German CML Study Group, Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.253 · Cited by 341
Self-citationKhoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C., Baccarani, M., Kim, D.-W., Zaritskey, A., Countouriotis, A., Besson, N., Leip, E., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390120 · Cited by 324
Self-citationSasaki, K., Strom, S. S., O'Brien, S., Jabbour, E., Ravandi, F., Konopleva, M., Borthakur, G., Pemmaraju, N., Daver, N., Jain, P., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00048-4 · Cited by 318
Self-citationMoving treatment-free remission into mainstream clinical practice in CML
Hughes, T. P., & Ross, D. M. (2016) · Blood · doi:10.1182/blood-2016-01-694265 · Cited by 317
Self-citationHehlmann, R., Müller, M. C., Lauseker, M., Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., Pletsch, N., Pfirrmann, M., Haferlach, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.9020 · Cited by 300
Self-citationGiles, F. J., le Coutre, P. D., Pinilla-Ibarz, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G., Hughes, T. P., et al. (2013) · Leukemia · doi:10.1038/leu.2012.181 · Cited by 251
Self-citationEide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Self-citationPatel, A. B., O’Hare, T., & Deininger, M. W. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.007 · Cited by 204
Shah, N. P., Rousselot, P., Schiffer, C., Rea, D., Cortes, J. E., Milone, J., Mohamed, H., Healey, D., Kantarjian, H., Hochhaus, A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24423 · Cited by 181
Self-citationJabbour, E., Kantarjian, H., & Cortes, J. (2015) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2015.03.006 · Cited by 164
Self-citationGarg, R. J., Kantarjian, H., O'Brien, S., Quintás-Cardama, A., Faderl, S., Estrov, Z., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2009-05-221531 · Cited by 164
Self-citationManley, P. W., Barys, L., & Cowan‐Jacob, S. W. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106458 · Cited by 153
Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
Cortes, J. E., Réa, D., & Lipton, J. H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25342 · Cited by 144
Self-citationHochhaus, A., Breccia, M., Saglio, G. N., García‐Gutiérrez, V., Réa, D., Janssen, J. J. W. M., & Apperley, J. F. (2020) · Leukemia · doi:10.1038/s41375-020-0842-9 · Cited by 116
Self-citationThe Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR–ABL
Hantschel, O. D., Grebien, F., & Superti‐Furga, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1276 · Cited by 114
Cortes, J. E., Khoury, H. J., Kantarjian, H. M., Lipton, J. H., Kim, D., Schafhausen, P., Matczak, E. M., Leip, E. P., Noonan, K., Brümmendorf, T. H., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24536 · Cited by 112
Self-citationLong-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
Castagnetti, F., Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.152 · Cited by 94
Hochhaus, A., Gambacorti-Passerini, C. B., Abboud, C. N., Gjertsen, B. T., Brümmendorf, T. H., Smith, B. D., Ernst, T., Giraldo-Castellano, P., Olsson‐Strömberg, U., Saußele, S., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0915-9 · Cited by 85
Self-citationChronic Myeloid Leukemia: Mechanisms of Resistance and Treatment
Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.004 · Cited by 68
Self-citationÉtienne, G., Dulucq, S., Nicolini, F. E., Morisset, S., Fort, M.-P., Schmitt, A., Etienne, M., Hayette, S., Lippert, É., Bureau, C., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.095158 · Cited by 62
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
Molica, M., Scalzulli, E., Colafigli, G., Foà, R., & Breccia, M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719826444 · Cited by 43
Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors
Chopade, P., & Akard, L. P. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.029 · Cited by 35
García‐Gutiérrez, V., Martínez‐Trillos, A., Lorenzo, J. L. L., Bautista, G., Mateos, M. L. M., Álvarez‐Larrán, A., Pérez, A. I., Collado, A. R., Fernandez, A., Portero, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23973 · Cited by 20
Self-citation
Cited by
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
Jabbour, E., & Kantarjian, H. (2022) · American Journal of Hematology · doi:10.1002/ajh.26642 · Cited by 281
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
Hochhaus, A., Wang, J., Kim, D.-W., Kim, D. D. H., Mayer, J., Goh, Y.-T., le Coutre, P., Takahashi, N., Kim, I., Etienne, G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400858 · Cited by 171
Self-citationHochhaus, A., Réa, D., Boquimpani, C., Minami, Y., Cortes, J. E., Hughes, T. P., Apperley, J. F., Lomaia, E., Voloshin, S., Turkina, A., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01829-9 · Cited by 148
Self-citationCortes, J. E., Sasaki, K., Kim, D.-W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02278-8 · Cited by 56
Self-citationMauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01860-w · Cited by 53
Self-citation
Metadata
- Authors
- Réa, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., Turkina, A., Kim, D.-W., Apperley, J. F., Abdo, A., Fogliatto, L. M., Kim, D. D. H., le Coutre, P., Saussele, S., Annunziata, M., Hughes, T. P., Chaudhri, N., Sasaki, K., Chee, L., García-Gutiérrez, V., Cortes, J. E., Aimone, P., Allepuz, A., Quenet, S., Bédoucha, V., & Hochhaus, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-11-25
- Volume
- 138
- Issue
- 21
- Pages
- 2031-2041
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3195243079
- Cited by
- 342
- References
- 31
- FWCI
- 32.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.